NasdaqGS:EXELBiotechs
Exelixis (EXEL) Is Up 6.1% After FDA Accepts Colorectal Cancer Combo NDA - What's Changed
In early February 2026, Exelixis, Inc. reported that the FDA accepted its New Drug Application for zanzalintinib plus atezolizumab to treat previously treated adult patients with metastatic colorectal cancer, granting a standard review with a target action date of December 3, 2026.
The filing draws on phase 3 STELLAR-303 data showing a statistically significant overall survival benefit versus regorafenib, highlighting how Exelixis is extending its kinase-inhibitor expertise beyond...